The Food and Drug Administration (FDA) has unveiled a new plan to improve
drug safety monitoring, which includes the creation of an independent Drug
Safety Oversight Board. Acting FDA Commissioner Lester M. Crawford, DVM, PhD,
who was nominated last month by President Bush to assume the post permanently,
announced the plan’s specific proposals, which will focus on making
the FDA’s review and decision-making processes more independent and
Hampton T. Drug Safety Monitoring. JAMA. 2005;293(12):1440. doi:10.1001/jama.293.12.1440-d
Customize your JAMA Network experience by selecting one or more topics from the list below.